Q3680814 (Q3680814): Difference between revisions
Jump to navigation
Jump to search
(Changed label, description and/or aliases in en: Setting new description) |
(Created claim: summary (P836): The Institute for Biomedical Research and Innovation of I-faute-Normandie (IRIB), established in 2012 federative structure, is a member of a research network of the GRR Chemistry-Biologie-Health. Since its inception, he has contributed significantly to the structuring of biomedical research at the University of Rouen-Normandie by coordinating, in conjunction with the CHU — Hospitals of Rouen, the activity of the Founding Units around a common un...) |
||||||||||||||
| Property / summary | |||||||||||||||
The Institute for Biomedical Research and Innovation of I-faute-Normandie (IRIB), established in 2012 federative structure, is a member of a research network of the GRR Chemistry-Biologie-Health. Since its inception, he has contributed significantly to the structuring of biomedical research at the University of Rouen-Normandie by coordinating, in conjunction with the CHU — Hospitals of Rouen, the activity of the Founding Units around a common unifying theme: the development of a high-level biomedical research focused on the understanding of the physiopathology of diseases and the development of new diagnostic and therapeutic tools.The IIB is currently consolidating the competences of 19 Research Units of the University of Rouen, all labelled (6 Mixed Units of Inserm Research — University of Rouen, a Multi-site Inserm Unit, an Inserm Team — Region — University of Rouen, 2 CNRS Joint Research Units — University of Rouen, 8 Hospital Teams from the University of Rouen and a CIC — Inserm — CHU de Rouen. In order to carry out the research programmes, the IRIB has set up an important technical platform consisting, inter alia, of the Centre d’Investigation Clinique (CIC), the Regional Platform for Research in Cellular Imagery of Normandy (PRIMACEN), the Instrumental Platform in Separative and Analytical Sciences of Rouen (Pissaro), the Platform for Behavioural Analysis (SCAC) certified by the GIS IBiSA and of 5 common high-performance services genomic analysis, small animal imaging (pictur), flow and cell sorting cytometry (CyFlow), oxidative stress assessment (BOSS) and the Centre for Innovation and Engineering in Organic Chemistry and Analysis (C21OrgA) as well as two pooled central animal plants located respectively at the Faculty of Science and the Faculty of Medicine-P Pharmacy, which are widely open to the scientific community but also to industry.Translational research or transfer research has emerged over the past twenty years as an expression of an essential need for the promises of fundamental research to be rapidly translated into improved health of individuals and populations and better patient management. Translational research is therefore based on bidirectional exchanges between exploratory researchers, clinicians and epidemiologists to design and validate new preventive, diagnostic, prognostic or therapeutic strategies.In the context of France’s backlog in translational research, the strategic scientific objective of the IIB is to become a reference centre in this field, building on the skills and synergies of the 19 teams of chemists. physicochemists, biochemists, pharmacologists and clinicians, in a continuum ranging from the most fundamental research to clinical applications, in coherence with the Chemistry-Biology-Health technopole.Thus, within the IIB, this translational research focuses in particular on public health problems both at regional and national level, and by way of example, the IRIB teams have developed new diagnostic markers and therapeutic strategies in the areas of Alzheimer’s disease, neonatal disability, cancer, cardiovascular disease, digestive diseases and nutrition, and these advances have been disseminated nationally and internationally.In order to achieve this ambitious goal, the IIB wants to continue to promote Translational Actions in Chemistry-Biology-Health (PACT-CBS) by strengthening the resources (technical and human) of the IIB’s technical trays. so that they can respond positively to the growing needs of cross-cutting multidisciplinary projects (13 projects) and thesis (6 projects). (English) | |||||||||||||||
| Property / summary: The Institute for Biomedical Research and Innovation of I-faute-Normandie (IRIB), established in 2012 federative structure, is a member of a research network of the GRR Chemistry-Biologie-Health. Since its inception, he has contributed significantly to the structuring of biomedical research at the University of Rouen-Normandie by coordinating, in conjunction with the CHU — Hospitals of Rouen, the activity of the Founding Units around a common unifying theme: the development of a high-level biomedical research focused on the understanding of the physiopathology of diseases and the development of new diagnostic and therapeutic tools.The IIB is currently consolidating the competences of 19 Research Units of the University of Rouen, all labelled (6 Mixed Units of Inserm Research — University of Rouen, a Multi-site Inserm Unit, an Inserm Team — Region — University of Rouen, 2 CNRS Joint Research Units — University of Rouen, 8 Hospital Teams from the University of Rouen and a CIC — Inserm — CHU de Rouen. In order to carry out the research programmes, the IRIB has set up an important technical platform consisting, inter alia, of the Centre d’Investigation Clinique (CIC), the Regional Platform for Research in Cellular Imagery of Normandy (PRIMACEN), the Instrumental Platform in Separative and Analytical Sciences of Rouen (Pissaro), the Platform for Behavioural Analysis (SCAC) certified by the GIS IBiSA and of 5 common high-performance services genomic analysis, small animal imaging (pictur), flow and cell sorting cytometry (CyFlow), oxidative stress assessment (BOSS) and the Centre for Innovation and Engineering in Organic Chemistry and Analysis (C21OrgA) as well as two pooled central animal plants located respectively at the Faculty of Science and the Faculty of Medicine-P Pharmacy, which are widely open to the scientific community but also to industry.Translational research or transfer research has emerged over the past twenty years as an expression of an essential need for the promises of fundamental research to be rapidly translated into improved health of individuals and populations and better patient management. Translational research is therefore based on bidirectional exchanges between exploratory researchers, clinicians and epidemiologists to design and validate new preventive, diagnostic, prognostic or therapeutic strategies.In the context of France’s backlog in translational research, the strategic scientific objective of the IIB is to become a reference centre in this field, building on the skills and synergies of the 19 teams of chemists. physicochemists, biochemists, pharmacologists and clinicians, in a continuum ranging from the most fundamental research to clinical applications, in coherence with the Chemistry-Biology-Health technopole.Thus, within the IIB, this translational research focuses in particular on public health problems both at regional and national level, and by way of example, the IRIB teams have developed new diagnostic markers and therapeutic strategies in the areas of Alzheimer’s disease, neonatal disability, cancer, cardiovascular disease, digestive diseases and nutrition, and these advances have been disseminated nationally and internationally.In order to achieve this ambitious goal, the IIB wants to continue to promote Translational Actions in Chemistry-Biology-Health (PACT-CBS) by strengthening the resources (technical and human) of the IIB’s technical trays. so that they can respond positively to the growing needs of cross-cutting multidisciplinary projects (13 projects) and thesis (6 projects). (English) / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / summary: The Institute for Biomedical Research and Innovation of I-faute-Normandie (IRIB), established in 2012 federative structure, is a member of a research network of the GRR Chemistry-Biologie-Health. Since its inception, he has contributed significantly to the structuring of biomedical research at the University of Rouen-Normandie by coordinating, in conjunction with the CHU — Hospitals of Rouen, the activity of the Founding Units around a common unifying theme: the development of a high-level biomedical research focused on the understanding of the physiopathology of diseases and the development of new diagnostic and therapeutic tools.The IIB is currently consolidating the competences of 19 Research Units of the University of Rouen, all labelled (6 Mixed Units of Inserm Research — University of Rouen, a Multi-site Inserm Unit, an Inserm Team — Region — University of Rouen, 2 CNRS Joint Research Units — University of Rouen, 8 Hospital Teams from the University of Rouen and a CIC — Inserm — CHU de Rouen. In order to carry out the research programmes, the IRIB has set up an important technical platform consisting, inter alia, of the Centre d’Investigation Clinique (CIC), the Regional Platform for Research in Cellular Imagery of Normandy (PRIMACEN), the Instrumental Platform in Separative and Analytical Sciences of Rouen (Pissaro), the Platform for Behavioural Analysis (SCAC) certified by the GIS IBiSA and of 5 common high-performance services genomic analysis, small animal imaging (pictur), flow and cell sorting cytometry (CyFlow), oxidative stress assessment (BOSS) and the Centre for Innovation and Engineering in Organic Chemistry and Analysis (C21OrgA) as well as two pooled central animal plants located respectively at the Faculty of Science and the Faculty of Medicine-P Pharmacy, which are widely open to the scientific community but also to industry.Translational research or transfer research has emerged over the past twenty years as an expression of an essential need for the promises of fundamental research to be rapidly translated into improved health of individuals and populations and better patient management. Translational research is therefore based on bidirectional exchanges between exploratory researchers, clinicians and epidemiologists to design and validate new preventive, diagnostic, prognostic or therapeutic strategies.In the context of France’s backlog in translational research, the strategic scientific objective of the IIB is to become a reference centre in this field, building on the skills and synergies of the 19 teams of chemists. physicochemists, biochemists, pharmacologists and clinicians, in a continuum ranging from the most fundamental research to clinical applications, in coherence with the Chemistry-Biology-Health technopole.Thus, within the IIB, this translational research focuses in particular on public health problems both at regional and national level, and by way of example, the IRIB teams have developed new diagnostic markers and therapeutic strategies in the areas of Alzheimer’s disease, neonatal disability, cancer, cardiovascular disease, digestive diseases and nutrition, and these advances have been disseminated nationally and internationally.In order to achieve this ambitious goal, the IIB wants to continue to promote Translational Actions in Chemistry-Biology-Health (PACT-CBS) by strengthening the resources (technical and human) of the IIB’s technical trays. so that they can respond positively to the growing needs of cross-cutting multidisciplinary projects (13 projects) and thesis (6 projects). (English) / qualifier | |||||||||||||||
point in time: 18 November 2021
| |||||||||||||||
Revision as of 17:43, 18 November 2021
Project Q3680814 in France
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | No label defined |
Project Q3680814 in France |
Statements
1,430,800.00 Euro
0 references
2,980,877.0 Euro
0 references
48.0 percent
0 references
31 December 2019
0 references
UNIVERSITE DE ROUEN-NORMANDIE
0 references
76821
0 references
L'Institut de Recherche et d'Innovation Biomédicale de I-faute-Normandie (IRIB), créé en 2012 structure fédérative, est membre un réseau de recherche du GRR Chimie-Biologie-Santé. Depuis sa création, il a fortement contribué à la structuration de la recherche biomédicale à l'Université de Rouen- Normandie en coordonnant, en lien avec le CHU -- Hôpitaux de Rouen, l'activité des Unités fondatrices autour d'un thème fédérateur commun: le développement d'une recherche biomédicale de haut-niveau focalisée sur la compréhension de la physiopathologie des maladies et le développement de nouveaux outils diagnostiques et thérapeutiques.L'IRIB fédère actuellement les compétences de 19 Unités de recherche de l'Université de Rouen, toutes labellisées (6 Unités Mixtes de Recherche Inserm - Université de Rouen, une Unité Inserm multi-site, une Equipe Inserm - Région - Université de Rouen, 2 Unités Mixtes de Recherche CNRS - Université de Rouen, 8 Equipes d'Accueil de l'Université de Rouen et un CIC - Inserm - CHU de Rouen. Pour mener à bien les programmes de recherche, l'IRIB a mis en place un important plateau technique constitué notamment, du Centre d'Investigation Clinique (CIC), de la Plate-Forme Régionale de Recherche en Imagerie Cellulaire de Normandie (PRIMACEN), de la Plate-Forme Instrumentale en Sciences Séparatives et Analytiques de Rouen (PISSARO), de la Plate-Forme d'Analyse Comportementale (SCAC) labellisées par le GIS IBiSA et de 5 services communs très performants analyse génomique, imagerie du petit animal (PICTUR), cytométrie en flux et de tri cellulaire (CyFlow), évaluation du stress oxydatif (BOSS) et le centre d'innovation et d'ingénierie en chimie organique et analyse (C21OrgA) ainsi que deux animaleries centrales mutualisées situées respectivement sur les sites de la Faculté des Sciences et de la Faculté de Médecine- Pharmacie, largement ouverts à la communauté scientifique mais également aux industriels.La recherche translationnelle ou recherche de transfert s'est imposée au cours de ces vingt dernières année comme l'expression d'un besoin essentiel pour que les promesses de la recherche fondamentale se traduisent rapidement par une amélioration de la santé des individus et des populations ainsi qu'une meilleure prise en charge des patients. De ce fait, la recherche translationnelle se base suc les échanges bidirectionnelles entre chercheurs exploratoires, cliniciens et épidémiologistes pour concevoir et valider les nouvelles stratégies préventives, diagnostiques, pronostiques ou thérapeutiques.Dans le contexte du retard que la France a accumulé dans le domaine de la recherche translationnelle, l'objectif scientifique stratégique de l'IRIB est de devenir un centre de référence dans ce domaine en s'appuyant sur les compétences et les synergies des 19 équipes de chimistes, physicochimistes, biochimistes, pharmacologues et cliniciens, dans un continuum allant des recherches les plus fondamentales jusqu'aux applications cliniques, en cohérence avec la technopole Chimie-Biologie-Santé.Ainsi, au sein de l'IRIB, cette recherche translationnelle est focalisée en particulier sur des problèmes de santé publique à la fois à l'échelon régional et national, et à titre d'exemples, les équipes de l'IRIB ont développé de nouveaux marqueurs diagnostiques et de nouvelles stratégies thérapeutiques dans les domaines de la maladie d'Alzheimer, du handicap néonatal, du cancer, des maladies cardiovasculaires, des maladies digestives et de la nutrition et ces avancées ont été diffusées au niveau national et international.Pour mener à bien cet objectif ambitieux, l'IRIB souhaite poursuivre la Promotion des Actions Translationnelles en Chimie-Biologie-Santé (PACT-CBS) en renforçant les moyens (techniques et humains) des plateaux techniques de l'IRIB, afin qu'ils puissent répondre favorablement aux besoins sans cesse croissante des projets multidisciplinaires transversaux (13 projets) et de thèse (6 projets). (French)
0 references
The Institute for Biomedical Research and Innovation of I-faute-Normandie (IRIB), established in 2012 federative structure, is a member of a research network of the GRR Chemistry-Biologie-Health. Since its inception, he has contributed significantly to the structuring of biomedical research at the University of Rouen-Normandie by coordinating, in conjunction with the CHU — Hospitals of Rouen, the activity of the Founding Units around a common unifying theme: the development of a high-level biomedical research focused on the understanding of the physiopathology of diseases and the development of new diagnostic and therapeutic tools.The IIB is currently consolidating the competences of 19 Research Units of the University of Rouen, all labelled (6 Mixed Units of Inserm Research — University of Rouen, a Multi-site Inserm Unit, an Inserm Team — Region — University of Rouen, 2 CNRS Joint Research Units — University of Rouen, 8 Hospital Teams from the University of Rouen and a CIC — Inserm — CHU de Rouen. In order to carry out the research programmes, the IRIB has set up an important technical platform consisting, inter alia, of the Centre d’Investigation Clinique (CIC), the Regional Platform for Research in Cellular Imagery of Normandy (PRIMACEN), the Instrumental Platform in Separative and Analytical Sciences of Rouen (Pissaro), the Platform for Behavioural Analysis (SCAC) certified by the GIS IBiSA and of 5 common high-performance services genomic analysis, small animal imaging (pictur), flow and cell sorting cytometry (CyFlow), oxidative stress assessment (BOSS) and the Centre for Innovation and Engineering in Organic Chemistry and Analysis (C21OrgA) as well as two pooled central animal plants located respectively at the Faculty of Science and the Faculty of Medicine-P Pharmacy, which are widely open to the scientific community but also to industry.Translational research or transfer research has emerged over the past twenty years as an expression of an essential need for the promises of fundamental research to be rapidly translated into improved health of individuals and populations and better patient management. Translational research is therefore based on bidirectional exchanges between exploratory researchers, clinicians and epidemiologists to design and validate new preventive, diagnostic, prognostic or therapeutic strategies.In the context of France’s backlog in translational research, the strategic scientific objective of the IIB is to become a reference centre in this field, building on the skills and synergies of the 19 teams of chemists. physicochemists, biochemists, pharmacologists and clinicians, in a continuum ranging from the most fundamental research to clinical applications, in coherence with the Chemistry-Biology-Health technopole.Thus, within the IIB, this translational research focuses in particular on public health problems both at regional and national level, and by way of example, the IRIB teams have developed new diagnostic markers and therapeutic strategies in the areas of Alzheimer’s disease, neonatal disability, cancer, cardiovascular disease, digestive diseases and nutrition, and these advances have been disseminated nationally and internationally.In order to achieve this ambitious goal, the IIB wants to continue to promote Translational Actions in Chemistry-Biology-Health (PACT-CBS) by strengthening the resources (technical and human) of the IIB’s technical trays. so that they can respond positively to the growing needs of cross-cutting multidisciplinary projects (13 projects) and thesis (6 projects). (English)
18 November 2021
0 references
Identifiers
17P04715
0 references